Decision to operate on hepatocellular cancer patients is not driven by comorbidities in Louisiana.

Background: The mortality rate of Hepatocellular cancer (HCC) in Louisiana is second worst in the United States. This has been linked to underutilization of curative treatment (CT). This study aimed to identify risk factors associated with underutilization of CT in Louisiana.

Medicaid Expansion Increases Treatment for Patients with Colon Cancer.

Introduction: Medicaid expansion (ME) has positively impacted colon cancer screening. ME's effect on colon cancer treatment is less clear. This study analyses the effect of ME on patterns of colon cancer treatment.

Disparities in Access to Care in the Multimodal Treatment of Primary Nonmetastatic Liver Cancers and Their Impact on Patient Outcomes.

Background: Liver cancer incidence and mortality have been shown to differ by race, ethnicity, and geography. This study aims to analyze disparities in the multimodal treatment of liver cancers in Louisiana.

Methods: Cases of nonmetastatic liver cancer in Louisiana from 2010 to 2020 were obtained from the Louisiana Tumor Registry.

Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade.

Members of the genus including Jurona virus (JURV) have emerged as promising immunotherapeutic agents, characterized by their tumor selectivity, fast kinetics, low seroprevalence, and minimal toxicity in humans. Here, we demonstrate that the administration of JURV leads to tumor regression in both hepatocellular carcinoma (HCC) xenograft and syngeneic models. Furthermore, our findings indicate that combining JURV and anti-PD-1 therapy reduced tumor burden and improved survival rates over JURV or anti-PD-1 alone in an orthotopic HCC model.

Healthcare disparities in access to surgical management and outcomes of patients with nonmetastatic primary liver cancer: A population based study from Louisiana tumor registry.

Background: This study aims to identify factors associated with disparities in receipt and outcomes of surgical interventions in patients with primary nonmetastatic liver cancers.

Methods: Cases from 2010 to 2020 were identified using Louisiana Tumor Registry. Four surgical categories were utilized: none, ablation, resection, transplant.